Flavones and Flavonols may have Clinical Potential as CK2 Inhibitors in Cancer Therapy
DOI:
https://doi.org/10.17140/CSMMOJ-2-105Keywords:
Cancer, CK2, CX-4945, Hsp90, Flavones, Flavonols, Xenografts, Betaglucuronidase, HDA6, SulforaphaneAbstract
The serine-threonine kinase CK2, which targets over 300 cellular proteins, is over expressed in all cancers, presumably reflecting its ability to promote proliferation, spread, and survival through a wide range of complementary mechanisms. Via an activating phosphorylation of Cdc373, a co-chaperone which partners with Hsp90, CK2 prolongs the half-life of protein kinases that promote proliferation and survival in many cancers, including Akt, Src, EGFR, Raf-1, and several cyclin-dependent kinases. CK2 works in other ways to boost the activity of signaling pathways that promote cancer aggressiveness and chemoresistance, including those driven by Akt, NF-kappaB, hypoxia-inducible factor-1, beta-catenin, STAT3, hedgehog, Notch1, and the androgen receptor; it also promotes the epidermal-mesenchymal transition and aids efficiency of DNA repair. Several potent and relatively specific inhibitors of CK2 are now being evaluated as potential cancer drugs; CX-4945 has shown impressive activity in cell culture studies and xenograft models, and is now entering clinical trials. Moreover, it has long been recognized that the natural flavone apigenin can inhibit CK2, with a Ki near 1 micromolar; more recent work indicates that a range of flavones and flavonols, characterized by a planar structure and hydroxylations at the 7 and 4’ positions - including apigenin, luteolin, keampferol, fisetin, quercetin, and myricetin - can inhibit CK2 with Ki s in the sub-micromolar range. This finding is particularly intriguing in light of the numerous studies demonstrating that each of these agents can inhibit the growth of cancer cells lines in vitro and of human xenografts in nude mice. These studies attribute the cancer-retardant efficacy of flavones/flavonols to impacts on a bewildering array of cellular targets, including those whose activities are boosted by CK2; it is reasonable to suspect that, at least in physiologically achievable concentrations, these agents may be achieving these effects primarily via CK2 inhibition. Inefficient absorption and rapid conjugation limit the bioefficacy of orally administered flavonoids; however, the increased extracellular beta-glucuronidase of many tumors may give tumors privileged access to glucuronidated flavonoids, and nanopartical technology can improve the bioavailability of these agents. Enzymatically modified isoquercitrin has particular promise as a delivery vehicle for quercetin. Hence, it may be worthwhile to explore the clinical potential of flavones/flavonols as CK2 inhibitors for cancer therapy.
References
Meggio F, Pinna LA. One-thousand-and-one substrates of pro-tein kinase CK2? FASEB J. 2003; 17(3): 349-368. doi: 10.1096/ fj.02-0473rev
Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol Histopathol. 2001; 16(2): 573-582.
Miyata Y, Nishida E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol. 2004; 24(9): 4065-4074. doi: 10.1128/ MCB.24.9.4065-4074.2004
Zhao M, Ma J, Zhu HY, et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 2011; 10: 104. doi: 10.1186/1476-4598-10-104
Miyata Y, Nishida E. Evaluating CK2 activity with the anti-body specific for the CK2-phosphorylated form of a kinase-tar-geting cochaperone Cdc37. Mol Cell Biochem. 2008; 316(1-2): 127-134. doi: 10.1007/s11010-008-9818-1
Di MG, Brustolon F, Pinna LA, Ruzzene M. Dephosphory-lation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci. 2009; 66(20): 3363-3373. doi: 10.1007/s00018-009-0108-1
Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits an-titumor efficacy. Cancer Res. 2010; 70(24): 10288-10298. doi: 10.1158/0008-5472.CAN-10-1893
Shehata M, Schnabl S, Demirtas D, et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood. 2010; 116(14): 2513-2521. doi: 10.1182/blood-2009-10-248054
Barata JT. The impact of PTEN regulation by CK2 on PI3K-de-pendent signaling and leukemia cell survival. Adv Enzyme Regul. 2011; 51(1): 37-49. doi: 10.1016/j.advenzreg.2010.09.012
Kang NI, Yoon HY, Kim HA, et al. Protein kinase CK2/ PTEN pathway plays a key role in platelet-activating factor-me-diated murine anaphylactic shock. J Immunol. 2011 1; 186(11): 6625-6632. doi: 10.4049/jimmunol.1100007
Chatterjee A, Chatterjee U, Ghosh MK. Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-depen-dent manner: implications in human prostate cancer. Cell Death Dis. 2013; 4: e543. doi: 10.1038/cddis.2013.63
Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE. Roles of IKK kinases and pro-tein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res. 2001; 61(9): 3810-3818.
Shen J, Channavajhala P, Seldin DC, Sonenshein GE. Phos-phorylation by the protein kinase CK2 promotes calpain-medi-ated degradation of IkappaBalpha. J Immunol. 2001; 167(9): 4919-4925. doi: 10.4049/jimmunol.167.9.4919
Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Son-enshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 2002; 62(22): 6770-6778.
Kato T, Jr., Delhase M, Hoffmann A, Karin M. CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activa-tion during the UV Response. Mol Cell. 2003; 12(4): 829-839.
Cavin LG, Romieu-Mourez R, Panta GR, et al. Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein sta-bilization and apoptosis of immortalized hepatocytes. Hepatol-ogy. 2003; 38(6): 1540-1551. doi: 10.1016/j.hep.2003.09.019
Eddy SF, Guo S, Demicco EG, et al. Inducible IkappaB ki-nase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res. 2005; 65(24): 11375-11383. doi: 10.1158/0008-5472.CAN-05-1602
Piazza FA, Ruzzene M, Gurrieri C, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood. 2006; 108(5): 1698-1707. doi: 10.1182/blood-2005-11-013672
Yu M, Yeh J, Van WC. Protein kinase casein kinase 2 me-diates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(sin head and neck squamous carcinoma cells. Cancer Res. 2006; 66(13): 6722-6731. doi: 10.1158/0008-5472.CAN-05-3758
Parhar K, Morse J, Salh B. The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling. Int J Colorectal Dis. 2007; 22(6): 601-609. doi: 10.1007/s00384-006-0193-7
Hamacher R, Saur D, Fritsch R, Reichert M, Schmid RM, Schneider G. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Oncol Rep. 2007; 18(3): 695-701. doi: 10.3892/or.18.3.695
Dominguez I, Sonenshein GE, Seldin DC. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci. 2009; 66(11-12): 1850-1857. doi: 10.1007/s00018-009- 9153-z
Brown MS, Diallo OT, Hu M, et al. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules. Clin Cancer Res. 2010; 16(8): 2295-2307. doi: 10.1158/1078-0432.CCR-09-3200
Tsuchiya Y, Asano T, Nakayama K, Kato T, Jr., Karin M, Kamata H. Nuclear IKKbeta is an adaptor protein for IkappaBal-pha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol Cell. 2010; 39(4): 570-582. doi: 10.1016/j.mol-cel.2010.07.030
Trembley JH, Unger GM, Tobolt DK, et al. Systemic ad-ministration of antisense oligonucleotides simultaneously target-ing CK2alpha and alpha’ subunits reduces orthotopic xenograft prostate tumors in mice. Mol Cell Biochem. 2011; 356(1-2): 21- 35. doi: 10.1007/s11010-011-0943-x
Trembley JH, Unger GM, Korman VL, et al. Nanoencapsu-lated anti-CK2 small molecule drug or siRNA specifically tar-gets malignant cancer but not benign cells. Cancer Lett. 2012; 315(1): 48-58. doi: 10.1016/j.canlet.2011.10.007
Zheng Y, McFarland BC, Drygin D, et al. Targeting Protein Kinase CK2 Suppresses Pro-survival Signaling Pathways and Growth of Glioblastoma. Clin Cancer Res. 2013; 19(23): 6484- 6494. doi: 10.1158/1078-0432.CCR-13-0265
Mottet D, Ruys SP, Demazy C, Raes M, Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer. 2005; 117(5): 764-774. doi: 10.1002/ijc.21268
Hubert A, Paris S, Piret JP, Ninane N, Raes M, Michiels C. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. J Cell Sci. 2006; 119(Pt 16): 3351-3362. doi: 10.1242/jcs.03069
Ampofo E, Kietzmann T, Zimmer A, Jakupovic M, Mon-tenarh M, Gotz C. Phosphorylation of the von Hippel-Lindau protein (VHL by protein kinase CK2 reduces its protein stabil-ity and affects p53 and HIF-1alpha mediated transcription. Int J Biochem Cell Biol. 2010; 42(10): 1729-1735. doi: 10.1016/j. biocel.2010.07.008
Song DH, Sussman DJ, Seldin DC. Endogenous protein ki-nase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem. 2000; 275(31): 23790-23797. doi: 10.1074/ jbc.M909107199
Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC. CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. J Biol Chem. 2003; 278(26): 24018-24025. doi: 10.1074/jbc.M212260200
Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I. CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem. 2005; 274(1-2): 63-67. doi: 10.1007/s11010-005-3078-0
Tapia JC, Torres VA, Rodriguez DA, Leyton L, Quest AF. Casein kinase 2 (CK2increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-de-pendent transcription. Proc Natl Acad Sci U S A. 2006; 103(41): 15079-15084. doi: 10.1073/pnas.0606845103
Wang S, Jones KA. CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr Biol. 2006; 16(22): 2239- 2244. doi: 10.1016/j.cub.2006.09.034
Lee AK, Ahn SG, Yoon JH, Kim SA. Sox4 stimulates ss-catenin activity through induction of CK2. Oncol Rep. 2011; 25(2): 559-565. doi: 10.3892/or.2010.1091
Ponce DP, Maturana JL, Cabello P, et al. Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent up-regulation of beta-catenin transcriptional activity. J Cell Physiol. 2011; 226(7): 1953-1959. doi: 10.1002/jcp.22527
Ponce DP, Yefi R, Cabello P, et al. CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expres-sion of survivin and enhance cell survival. Mol Cell Biochem. 2011; 356(1-2): 127-132. doi: 10.1007/s11010-011-0965-4
Kim J, Hwan KS. CK2 Inhibitor CX-4945 Blocks TGF-beta1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells. PLoS ONE. 2013; 8(9): e74342.. doi: 10.1371/journal.pone.0074342
Piazza FA, Ruzzene M, Gurrieri C, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood. 2006; 108(5): 1698-1707. doi: 10.1182/blood-2005-11-013672
Lin YC, Hung MS, Lin CK, et al. CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation. Cancer Biother Radiop-harm. 2011; 26(3): 381-388. doi: 10.1089/cbr.2010.0917
Zhao M, Ma J, Zhu HY, et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 2011; 10: 104. doi: 10.1186/1476-4598-10-104
Zhang S, Wang Y, Mao JH, et al. Inhibition of CK2alpha down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS ONE. 2012; 7(6): e38996. doi: 10.1111/jcmm.12068
Zhang S, Long H, Yang YL, et al. Inhibition of CK2alpha down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med. 2013; 17(7): 854-862. doi: 10.1111/jcmm.12068
Ryu BJ, Baek SH, Kim J, et al. Anti-androgen receptor activ-ity of apoptotic CK2 inhibitor CX4945 in human prostate cancer LNCap cells. Bioorg Med Chem Lett. 2012; 22(17): 5470-5474. doi: 10.1016/j.bmcl.2012.07.031
Yao K, Youn H, Gao X, et al. Casein kinase 2 inhibition at-tenuates androgen receptor function and cell proliferation in prostate cancer cells. Prostate. 2012; 72(13): 1423-1430. doi: 10.1002/pros.22493
Gotz C, Bachmann C, Montenarh M. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor depen-dent transcription in prostate cancer cells. Prostate. 2007; 67(2): 125-134. doi: 10.1002/pros.20471
Loizou JI, El-Khamisy SF, Zlatanou A, et al. The protein ki-nase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell. 2004; 117(1): 17-28. doi: 10.1016/s0092-8674- (04)00206-5
Parsons JL, Dianova II, Finch D, et al. XRCC1 phospho-rylation by CK2 is required for its stability and efficient DNA repair. DNA Repair (Amst). 2010; 9(7): 835-841. doi: 10.1016/j. dnarep.2010.04.008
Strom CE, Mortusewicz O, Finch D, et al. CK2 phospho-rylation of XRCC1 facilitates dissociation from DNA and single-strand break formation during base excision repair. DNA Repair (Amst). 2011; 10(9): 961-969. doi: 10.1016/j. dnarep.2011.07.004
Siddiqui-Jain A, Bliesath J, Macalino D, et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther. 2012; 11(4): 994-1005. doi: 10.1158/1535-7163.MCT-11-0613
Chapman JR, Jackson SP. Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage. EMBO Rep. 2008; 9(8): 795-801. doi: 10.1038/embor.2008.103
Becherel OJ, Jakob B, Cherry AL, et al. CK2 phosphoryla-tion-dependent interaction between aprataxin and MDC1 in the DNA damage response. Nucleic Acids Res. 2010; 38(5): 1489- 1503. doi: 10.1093/nar/gkp1149
Belguise K, Guo S, Yang S, et al. Green tea polyphenols re-verse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res. 2007; 67(24): 11742-11750. doi: 10.1158/0008-5472.CAN-07-2730
MacPherson MR, Molina P, Souchelnytskyi S, et al. Phospho-rylation of serine 11 and serine 92 as new positive regulators of human Snail1 function: potential involvement of casein kinase-2 and the cAMP-activated kinase protein kinase A. Mol Biol Cell. 2010; 21(2): 244-253. doi: 10.1091/mbc.E09-06-0504
Su YW, Xie TX, Sano D, Myers JN. IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2. PLoS ONE. 2011; 6(4): e19412. doi: 10.1371/journal.pone.0019412
Zou J, Luo H, Zeng Q, Dong Z, Wu D, Liu L. Protein kinase CK2alpha is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. J Transl Med. 2011; 9: 97. doi: 10.1186/1479-5876-9-97
Kim J, Hwan KS. CK2 Inhibitor CX-4945 Blocks TGF-beta1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells. PLoS ONE. 2013; 8(9): e74342. doi: 10.1371/journal.pone.0074342
Deshiere A, Duchemin-Pelletier E, Spreux E, et al. Regula-tion of epithelial to mesenchymal transition: CK2beta on stage. Mol Cell Biochem. 2011; 356(1-2): 11-20. doi: 10.1007/s11010- 011-0942-y
Deshiere A, Duchemin-Pelletier E, Spreux E, et al. Unbal-anced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction. Onco-gene. 2013; 32(11): 1373-1383. doi: 10.1038/onc.2012.165
Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits an-titumor efficacy. Cancer Res. 2010; 70(24): 10288-10298. doi: 10.1158/0008-5472.CAN-10-1893
Pierre F, Chua PC, O’Brien SE, et al. Pre-clinical charac-terization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem. 2011; 356(1-2): 37-43. doi: 10.1007/s11010-011-0956-5
Siddiqui-Jain A, Bliesath J, Macalino D, et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther. 2012; 11(4): 994-1005. doi: 10.1158/1535-7163.MCT-11-0613
Song DH, Sussman DJ, Seldin DC. Endogenous protein ki-nase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem. 2000; 275(31): 23790-23797. doi: 10.1074/ jbc.M909107199
Liu LZ, Fang J, Zhou Q, Hu X, Shi X, Jiang BH. Apigenin inhibits expression of vascular endothelial growth factor and an-giogenesis in human lung cancer cells: implication of chemopre-vention of lung cancer. Mol Pharmacol. 2005; 68(3): 635-643. doi: 10.1124/mol.105.011254
Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J. 2005; 19(14): 2042-2044. doi: 10.1096/fj.05-3740fje
Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor an-giogenesis through decreasing HIF-1alpha and VEGF expres-sion. Carcinogenesis. 2007; 28(4): 858-864. doi: 10.1093/car-cin/bgl205
Hu XW, Meng D, Fang J. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal ad-hesion kinase. Carcinogenesis. 2008; 29(12): 2369-2376. doi: 10.1093/carcin/bgn244
Lamy S, Bedard V, Labbe D, et al. The dietary flavones apigenin and luteolin impair smooth muscle cell migration and VEGF expression through inhibition of PDGFR-beta phospho-rylation. Cancer Prev Res (Phila). 2008; 1(6): 452-459. doi: 10.1158/1940-6207.CAPR-08-0072
King JC, Lu QY, Li G, et al. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Bio-chim Biophys Acta. 2012; 1823(2): 593-604. doi: 10.1016/j. bbamcr.2011.12.008
Torkin R, Lavoie JF, Kaplan DR, Yeger H. Induction of cas-pase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol Cancer Ther. 2005; 4(1): 1-11.
Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther. 2006; 5(4): 843-852. doi: 10.1158/1535-7163. MCT-05-0370
Chen D, Landis-Piwowar KR, Chen MS, Dou QP. Inhibition of proteasome activity by the dietary flavonoid apigenin is asso-ciated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res. 2007; 9(6): R80. doi: 10.1186/ bcr1797
Kaur P, Shukla S, Gupta S. Plant flavonoid apigenin inacti-vates Akt to trigger apoptosis in human prostate cancer: an in vit-ro and in vivo study. Carcinogenesis. 2008; 29(11): 2210-2217. doi: 10.1093/carcin/bgn201
Shukla S, Gupta S. Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study. Mol Carcinog. 2009; 48(3): 243-252. doi: 10.1002/mc.20475
Cai J, Zhao XL, Liu AW, Nian H, Zhang SH. Apigenin inhib-its hepatoma cell growth through alteration of gene expression patterns. Phytomedicine. 2011; 18(5): 366-373. doi: 10.1016/j. phymed.2010.08.006
Wang QR, Yao XQ, Wen G, et al. Apigenin suppresses the growth of colorectal cancer xenografts via phosphorylation and up-regulated FADD expression. Oncol Lett. 2011; 2(1): 43-47.
Pandey M, Kaur P, Shukla S, Abbas A, Fu P, Gupta S. Plant flavone apigenin inhibits HDAC and remodels chromatin to in-duce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol Carcinog. 2012; 51(12): 952-962. doi: 10.1002/mc.20866
Budhraja A, Gao N, Zhang Z, et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther. 2012; 11(1): 132-142. doi: 10.1158/1535-7163.MCT-11-0343
Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM. Apigenin induces apoptosis and blocks growth of medroxy-progesterone acetate-dependent BT-474 xenograft tumors. Horm Cancer. 2012; 3(4): 160-171. doi: 10.1007/s12672-012-0114-x
Gao AM, Ke ZP, Wang JN, Yang JY, Chen SY, Chen H. Api-genin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/ Nrf2 pathway. Carcinogenesis. 2013; 34(8): 1806-1814. doi: 10.1093/carcin/bgt108
Hussain AR, Khan AS, Ahmed SO, et al. Apigenin induc-es apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells. Cell Prolif. 2010; 43(2): 170-183. doi: 10.1111/ j.1365-2184.2009.00662.x
He J, Xu Q, Wang M, et al. Oral Administration of Apigenin Inhibits Metastasis through AKT/P70S6K1/MMP-9 Pathway in Orthotopic Ovarian Tumor Model. Int J Mol Sci. 2012; 13(6): 7271-7282. doi: 10.3390/ijms13067271
Tong X, Pelling JC. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anticancer Agents Med Chem. 2013; 13(7): 971-978. doi: 10.2174/18715206113139990119
Gao AM, Ke ZP, Wang JN, Yang JY, Chen SY, Chen H. Api-genin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/ Nrf2 pathway. Carcinogenesis. 2013; 34(8): 1806-1814. doi: 10.1093/carcin/bgt108
Chunhua L, Donglan L, Xiuqiong F, et al. Apigenin up-regulates transgelin and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT. J Nutr Biochem. 2013; 24(10): 1766-1775. doi: 10.1016/j. jnutbio.2013.03.006
Osada M, Imaoka S, Funae Y. Apigenin suppresses the ex-pression of VEGF, an important factor for angiogenesis, in en-dothelial cells via degradation of HIF-1alpha protein. FEBS Lett. 2004; 575(1-3): 59-63.
Mottet D, Ruys SP, Demazy C, Raes M, Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer. 2005; 117(5): 764-774. doi: 10.1002/ijc.21268
Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor an-giogenesis through decreasing HIF-1alpha and VEGF expres-sion. Carcinogenesis. 2007; 28(4): 858-864. doi: 10.1093/car-cin/bgl205
Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog. 2008; 47(9): 686-700. doi: 10.1002/mc.20421
Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin down-regulates the hypoxia response genes: HIF-1alpha, GLUT-1, and VEGF in human pancreatic cancer cells. J Surg Res. 2011; 167(2): 173-181. doi: 10.1016/j.jss.2010.10.041
Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. On-cogene. 2002; 21(23): 3727-3738. doi: 10.1038/sj/onc/1205474
Lee SH, Ryu JK, Lee KY, et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pan-creatic cancer. Cancer Lett. 2008; 259(1): 39-49. doi: 10.1016/j. canlet.2007.09.015
Seo HS, Choi HS, Kim SR, et al. Apigenin induces apop-tosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFkappaB signaling in HER2-overexpressing breast cancer cells. Mol Cell Biochem. 2012; 366(1-2): 319-334. doi: 10.1007/ s11010-012-1310-2
Johnson JL, Gonzalez de ME. Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic can-cer cells, in vitro. Food Chem Toxicol. 2013; 60: 83-91. doi: 10.1016/j.fct.2013.07.036
Lamy S, Akla N, Ouanouki A, Lord-Dufour S, Beliveau R. Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Exp Cell Res. 2012; 318(13): 1586-1596. doi: 10.1016/j.yexcr.2012.04.004
Song DH, Sussman DJ, Seldin DC. Endogenous protein ki-nase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem. 2000; 275(31): 23790-23797. doi: 10.1074/ jbc.M909107199
Shukla S, MacLennan GT, Flask CA, et al. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses pros-tate carcinogenesis in TRAMP mice. Cancer Res. 2007; 67(14): 6925-6935. doi: 10.1158/0008-5472.CAN-07-0717
Slusarz A, Shenouda NS, Sakla MS, et al. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010; 70(8): 3382-3390. doi: 10.1158/0008- 5472.CAN-09-3012
Tsai CH, Lin FM, Yang YC, et al. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res. 2009; 15(17): 5435-5444. doi: 10.1158/1078-0432.CCR-09-0298
Lin FM, Chen LR, Lin EH, et al. Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis. 2007; 28(12): 2521- 2529. doi: 10.1093/carcin/bgm137
Cai X, Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA dam-age. Proc Natl Acad Sci U S A. 2008; 105(44): 16958-16963. doi: 10.1073/pnas.0804608105
Zhong Y, Krisanapun C, Lee SH, et al. Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur J Cancer. 2010; 46(18): 3365-3374. doi: 10.1016/j. ejca.2010.07.007
Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. Inhibi-tion of Casein kinase-2 induces p53-dependent cell cycle ar-rest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis. 2012; 3: e271. doi: 10.1038/cddis.2012.10
Choi EJ, Kim GH. Apigenin causes G(2)/M arrest associat-ed with the modulation of p21(Cip1and Cdc2 and activates p53- dependent apoptosis pathway in human breast cancer SK-BR-3 cells. J Nutr Biochem. 2009; 20(4): 285-290. doi: 10.1016/j.jnut-bio.2008.03.005
Shukla S, Gupta S. Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic Biol Med. 2008; 44(10): 1833-1845. doi: 10.1016/j. freeradbiomed.2008.02.007
Chiang LC, Ng LT, Lin IC, Kuo PL, Lin CC. Anti-prolifera-tive effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett. 2006; 237(2): 207-214. doi: 10.1016/j. canlet.2005.06.002
Zheng PW, Chiang LC, Lin CC. Apigenin induced apop-tosis through p53-dependent pathway in human cervical carci-noma cells. Life Sci. 2005; 76(12): 1367-1379. doi: 10.1016/j. lfs.2004.08.023
Takagaki N, Sowa Y, Oki T, Nakanishi R, Yogosawa S, Sakai T. Apigenin induces cell cycle arrest and p21/WAF1 ex-pression in a p53-independent pathway. Int J Oncol. 2005; 26(1): 185-189. doi: 10.3892/ijo.26.1.185
Lolli G, Cozza G, Mazzorana M, et al. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry. 2012; 51(31): 6097-6107. doi: 10.1021/bi300531c
Attoub S, Hassan AH, Vanhoecke B, et al. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activ-ity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol. 2011; 651(1-3): 18-25. doi: 10.1016/j. ejphar.2010.10.063
Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS. Luteo-lin induces apoptosis in oral squamous cancer cells. J Dent Res. 2008; 87(4): 401-406. doi: 10.1177/154405910808700413
Chiu FL, Lin JK. Downregulation of androgen receptor ex-pression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xe-nografts. Prostate. 2008; 68(1): 61-71. doi: 10.1002/pros.20690
Bagli E, Stefaniotou M, Morbidelli L, et al. Luteolin in-hibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by target-ing phosphatidylinositol 3’-kinase activity. Cancer Res. 2004; 64(21): 7936-7946. doi: 10.1158/0008-5472.CAN-03-3104
Selvendiran K, Koga H, Ueno T, et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor po-tential of flavonoids. Cancer Res. 2006; 66(9): 4826-4834. doi: 10.1158/0008-5472.CAN-05-4062
Shi R, Huang Q, Zhu X, et al. Luteolin sensitizes the anti-cancer effect of cisplatin via c-Jun NH2-terminal kinase-medi-ated p53 phosphorylation and stabilization. Mol Cancer Ther. 2007; 6(4): 1338-1347. doi: 10.1158/1535-7163.MCT-06-0638
Zhou Q, Yan B, Hu X, Li XB, Zhang J, Fang J. Luteolin in-hibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther. 2009; 8(6): 1684-1691. doi: 10.1158/1535- 7163.MCT-09-0191
Hwang JT, Park OJ, Lee YK, et al. Anti-tumor effect of lute-olin is accompanied by AMP-activated protein kinase and nucle-ar factor-kappaB modulation in HepG2 hepatocarcinoma cells. Int J Mol Med. 2011; 28(1): 25-31. doi: 10.3892/ijmm.2011.667
Tsai CH, Lin FM, Yang YC, et al. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res. 2009; 15(17): 5435-5444. doi: 10.1158/1078-0432.CCR-09-0298
Yan J, Wang Q, Zheng X, et al. Luteolin enhances TNF-related apoptosis-inducing ligand’s anticancer activity in a lung cancer xenograft mouse model. Biochem Biophys Res Commun. 2012; 417(2): 842-846. doi: 10.1016/j.bbrc.2011.12.055
Lee EJ, Oh SY, Sung MK. Luteolin exerts anti-tumor ac-tivity through the suppression of epidermal growth factor re-ceptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem Toxicol. 2012; 50(11): 4136-4143. doi: 10.1016/j.fct.2012.08.025
Pratheeshkumar P, Son YO, Budhraja A, et al. Luteolin in-hibits human prostate tumor growth by suppressing vascular en-dothelial growth factor receptor 2-mediated angiogenesis. PLoS ONE. 2012; 7(12): e52279. doi: 10.1371/journal.pone.0052279
Huang WW, Chiu YJ, Fan MJ, et al. Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondria-dependent pathway in human osteosarcoma U-2 OS cells. Mol Nutr Food Res. 2010; 54(11): 1585-1595. doi: 10.1002/ mnfr.201000005
Khan N, Asim M, Afaq F, Abu ZM, Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 2008; 68(20): 8555-8563. doi: 10.1158/0008-5472.CAN-08-0240
Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C. An-ticancer activity of a combination of cisplatin and fisetin in em-bryonal carcinoma cells and xenograft tumors. Mol Cancer Ther. 2011; 10(2): 255-268. doi: 10.1158/1535-7163.MCT-10-0606
Ying TH, Yang SF, Tsai SJ, et al. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated ac-tivation of caspase-8-/caspase-3-dependent pathway. Arch Toxi-col. 2012; 86(2): 263-273. doi: 10.1007/s00204-011-0754-6
Zhou W, Kallifatidis G, Baumann B, et al. Dietary polyphe-nol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010; 37(3): 551-561. doi: 10.3892/ijo_00000704
Zhong X, Wu K, He S, Ma S, Kong L. Effects of quercetin on the proliferation and apoptosis in transplantation tumor of breast cancer in nude mice. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003; 34(3): 439-442.
Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH, Huynh H. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with in-hibition of angiogenesis and cellular proliferation. Int J Oncol. 2004; 24(5): 1297-1304. doi: 10.3892/ijo.24.5.1297
Dechsupa S, Kothan S, Vergote J, et al. Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDA-mB-435 cells xenograft in vivo. Cancer Biol Ther. 2007; 6(1): 56-61. doi: 10.4161/cbt.6.1.3548
Sun ZJ, Chen G, Hu X, et al. Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apop-tosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis. 2010; 15(7): 850-863. doi: 10.1007/s10495-010-0497-5
Cheng S, Gao N, Zhang Z, et al. Quercetin induces tumor-selective apoptosis through downregulation of Mcl-1 and acti-vation of Bax. Clin Cancer Res. 2010; 16(23): 5679-5691. doi: 10.1158/1078-0432.CCR-10-1565
Long Q, Xiel Y, Huang Y, et al. Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers. J Biomed Nanotechnol. 2013; 9(6): 965-975. doi: http://dx.doi. org/10.1166/jbn.2013.1596
Huang CY, Chan CY, Chou IT, Lien CH, Hung HC, Lee MF. Quercetin induces growth arrest through activation of FOXO1 transcription factor in EGFR-overexpressing oral cancer cells. J Nutr Biochem. 2013; 24(9): 1596-1603. doi: 10.1016/j. jnutbio.2013.01.010
Chan ST, Yang NC, Huang CS, Liao JW, Yeh SL. Quercetin enhances the antitumor activity of trichostatin A through upregu-lation of p53 protein expression in vitro and in vivo. PLoS ONE. 2013; 8(1): e54255. doi: 10.1371/journal.pone.0054255
Wang G, Zhang J, Liu L, Sharma S, Dong Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS ONE. 2012; 7(12): e51764. doi: 10.1371/journal.pone.0051764
Pratheeshkumar P, Budhraja A, Son YO, et al. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting V EGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS ONE. 2012; 7(10): e47516. doi: 10.1371/jour-nal.pone.0047516
Gao X, Wang B, Wei X, et al. Anticancer effect and mecha-nism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale. 2012 21; 4(22): 7021-7030. doi: 10.1039/ c2nr32181e
Angst E, Park JL, Moro A, et al. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas. 2013; 42(2): 223-229. doi: 10.1097/MPA.0b013e318264ccae
Kim HS, Wannatung T, Lee S, et al. Quercetin enhances hypoxia-mediated apoptosis via direct inhibition of AMPK ac-tivity in HCT116 colon cancer. Apoptosis. 2012; 17(9): 938-949. doi: 10.1007/s10495-012-0719-0
Tan BJ, Liu Y, Chang KL, Lim BK, Chiu GN. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int J Nanomedicine. 2012; 7: 651-661. doi: 10.2147/ IJN.S26538
Zheng SY, Li Y, Jiang D, Zhao J, Ge JF. Anticancer ef-fect and apoptosis induction by quercetin in the human lung cancer cell line A-549. Mol Med Rep. 2012; 5(3): 822-826. doi: 10.3892/mmr.2011.726
Lin C, Yu Y, Zhao HG, Yang A, Yan H, Cui Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol. 2012; 104(3): 395-400. doi: 10.1016/j.radonc.2011.10.023
Wang K, Liu R, Li J, et al. Quercetin induces protective au-tophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1alpha-mediated signaling. Autophagy. 2011; 7(9): 966-978.
Wong MY, Chiu GN. Liposome formulation of co-encap-sulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nano-medicine. 2011; 7(6): 834-840. doi: 10.1016/j.nano.2011.02.001
Sun F, Zheng XY, Ye J, Wu TT, Wang J, Chen W. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer. 2012; 64(4): 599- 606. doi: 10.1080/01635581.2012.665564
Valentova K, Vrba J, Bancirova M, Ulrichova J, Kren V. Isoquercitrin: pharmacology, toxicology, and metabo-lism. Food Chem Toxicol. 2014; 68: 267-282. doi: 10.1016/j. fct.2014.03.018
Murota K, Matsuda N, Kashino Y, et al. alpha-Oligoglu-cosylation of a sugar moiety enhances the bioavailability of quercetin glucosides in humans. Arch Biochem Biophys. 2010; 501(1): 91-97. doi: 10.1016/j.abb.2010.06.036
Makino T, Shimizu R, Kanemaru M, Suzuki Y, Moriwaki M, Mizukami H. Enzymatically modified isoquercitrin, alpha-oligoglucosyl quercetin 3-O-glucoside, is absorbed more easily than other quercetin glycosides or aglycone after oral adminis-tration in rats. Biol Pharm Bull. 2009; 32(12): 2034-2040.
Kawai M, Hirano T, Arimitsu J, et al. Effect of enzymatical-ly modified isoquercitrin, a flavonoid, on symptoms of Japanese cedar pollinosis: a randomized double-blind placebo-controlled trial. Int Arch Allergy Immunol. 2009; 149(4): 359-368. doi: 10.1159/000205582
Motoyama K, Koyama H, Moriwaki M, et al. Atheropro-tective and plaque-stabilizing effects of enzymatically modi-fied isoquercitrin in atherogenic apoE-deficient mice. Nutrition. 2009; 25(4): 421-427. doi: 10.1016/j.nut.2008.08.013
Shia CS, Tsai SY, Kuo SC, Hou YC, Chao PD. Metabolism and pharmacokinetics of 3,3’,4’,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis ef-fects of fisetin and its serum metabolites. J Agric Food Chem. 2009; 57(1): 83-89. doi: 10.1021/jf802378q
FISHMAN WH, ANLYAN AJ. The presence of high be-ta-glucuronidase activity in cancer tissue. J Biol Chem. 1947; 169(2): 449.
Bosslet K, Straub R, Blumrich M, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998; 58(6): 1195-1201
Paigen K. Mammalian beta-glucuronidase: genetics, mo-lecular biology, and cell biology. Prog Nucleic Acid Res Mol Biol. 1989; 37: 155-205.
Estrella V, Chen T, Lloyd M, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013; 73(5): 1524-1535. doi: 10.1158/0008-5472.CAN-12- 2796
Murdter TE, Friedel G, Backman JT, et al. Dose optimiza-tion of a doxorubicin prodrug (HMR 1826in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. J Pharmacol Exp Ther. 2002; 301(1): 223- 228. doi: 10.1124/jpet.301.1.223
Sperker B, Werner U, Murdter TE, et al. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn Schmiedebergs Arch Pharmacol. 2000; 362(2): 110-115. doi: 10.1007/s002100000260
de GM, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. Beta-glucuronidase-mediated drug release. Curr Pharm Des. 2002; 8(15): 1391-1403. doi: 10.2174/1381612023394485
Yuan L, Wagatsuma C, Yoshida M, et al. Inhibition of hu-man breast cancer growth by GCP (genistein combined polysac-charidein xenogeneic athymic mice: involvement of genistein biotransformation by beta-glucuronidase from tumor tissues. Mutat Res. 2003; 523-524: 55-62. doi: 10.1016/s0027-5107- (02)00321-4
Chen X, Wu B, Wang PG. Glucuronides in anti-cancer ther-apy. Curr Med Chem Anticancer Agents. 2003; 3(2): 139-150. doi: 10.2174/1568011033353470
Oi N, Hashimoto T, Kanazawa K. Metabolic conversion of dietary quercetin from its conjugate to active aglycone following the induction of hepatocarcinogenesis in fisher 344 rats. J Agric Food Chem. 2008; 56(2): 577-583. doi: 10.1021/jf072556c
Murakami A, Ashida H, Terao J. Multitargeted cancer pre-vention by quercetin. Cancer Lett. 2008; 269(2): 315-325. doi: 10.1016/j.canlet.2008.03.046
Legigan T, Clarhaut J, Renoux B, et al. Synthesis and an-titumor efficacy of a beta-glucuronidase-responsive albumin-binding prodrug of doxorubicin. J Med Chem. 2012; 55(9): 4516-4520.
Chen KC, Schmuck K, Tietze LF, Roffler SR. Selective cancer therapy by extracellular activation of a highly potent gly-cosidic duocarmycin analogue. Mol Pharm. 2013; 10(5): 1773- 1782. doi: 10.1021/mp300581u
Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (wood). 2007; 232(2): 227-234.
Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29): 26729-26734. doi: 10.1074/jbc.C500186200
Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 2005; 15(11): 565-567. doi: 10.1016/j.tcb.2005.09.003
Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhanc-es 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood. 2008; 112(5): 1886-1893. doi: 10.1182/blood-2008-03-143644
Ai J, Wang Y, Dar JA, et al. HDAC6 regulates androgen re-ceptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol. 2009; 23(12): 1963-1972. doi: 10.1210/me.2009- 0188
Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A. 2009; 106(39): 16663-16668. doi: 10.1073/pnas.0908908106
Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011; 2011: 875824. doi: 10.1155/2011/875824
Kaliszczak M, Trousil S, Aberg O, Perumal M, Nguyen QD, Aboagye EO. A novel small molecule hydroxamate prefer-entially inhibits HDAC6 activity and tumour growth. Br J Can-cer. 2013; 108(2): 342-350. doi: 10.1038/bjc.2012.576
Wang P, Henning SM, Heber D, Vadgama JV. Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015. doi: 10.1016/j.jnutbio.2014.11.017
Chen FY, Cao LF, Wan HX, et al. Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells. Mol Med Rep. 2015; 11(1): 341-348. doi: 10.3892/mmr.2014.2734
Maciejczyk A, Surowiak P. Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. Ginekol Pol. 2013; 84(7): 590-595.
Han Y, Yu H, Wang J, Ren Y, Su X, Shi Y. Quercetin allevi-ates myocyte toxic and sensitizes anti-leukemic effect of adri-amycin. Hematology. 2014. doi: http://dx.doi.org/10.1179/1607 845414y.0000000198
Orsolic N, Car N. Quercetin and hyperthermia modulate cisplatin-induced DNA damage in tumor and normal tissues in vivo. Tumour Biol. 2014; 35(7): 6445-6454. doi: 10.1007/ s13277-014-1843-y
Papiez MA. The effect of quercetin on oxidative DNA dam-age and myelosuppression induced by etoposide in bone marrow cells of rats. Acta Biochim Pol. 2014; 61(1): 7-11.
Mahoney SE, Davis JM, Murphy EA, McClellan JL, Pena MM. Dietary quercetin reduces chemotherapy-induced fa-tigue in mice. Integr Cancer Ther. 2014; 13(5): 417-424. doi: 10.1177/1534735414523315
Azevedo MI, Pereira AF, Nogueira RB, et al. The antioxi-dant effects of the flavonoids rutin and quercetin inhibit oxalip-latin-induced chronic painful peripheral neuropathy. Mol Pain. 2013; 9: 53. doi: 10.1186/1744-8069-9-53
Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O’Brien C, Seldin DC. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol. 2008; 28(1): 131-139. doi: 10.1128/MCB.01119-07
Landesman-Bollag E, Belkina A, Hovey B, Connors E, Cox C, Seldin DC. Developmental and growth defects in mice with combined deficiency of CK2 catalytic genes. Mol Cell Biochem. 2011; 356(1-2): 227-231. doi: 10.1007/s11010-011-0967-2
Hasumura M, Yasuhara K, Tamura T, Imai T, Mitsumori K, Hirose M. Evaluation of the toxicity of enzymatically de-composed rutin with 13-weeks dietary administration to Wistar rats. Food Chem Toxicol. 2004; 42(3): 439-444. doi: 10.1016/j. fct.2003.10.006
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.